Featured Research

from universities, journals, and other organizations

Research Team Responds To Concerns About International Insulin Drug Trial

Date:
August 17, 2009
Source:
McMaster University
Summary:
Accumulating safety data from the large, international ORIGIN trial have been reviewed by its independent data monitoring committee, who have concluded that there is no cause for concern.

Accumulating safety data from the large, international ORIGIN trial have been reviewed by its independent data monitoring committee, who have concluded that there is no cause for concern.

This six-year study, which is lead by McMaster University professors Dr. Hertzel Gerstein and Dr. Salim Yusuf of the Population Health Research Institute, is determining whether insulin glargine and/or omega 3 fatty acids can reduce cardiovascular events in 12,578 people with elevated blood sugar levels from around the world.

The data monitoring committee, headed by Professor Rory Collins of the University of Oxford, is auditing the trial for safety, but did extra reviews recently after an article in the European journal Diabetologia in June suggested a connection between use of insulin glargine and cancer.

The committee reviewed all data collected to date in the two treatment groups and concluded there is no cause for concern. It also found no reason to alter the design of the study for safety reasons.

"The ORIGIN investigators are reassured by the findings of the independent data committee," said Dr. Gerstein. "We look forward to continuing this trial, which will provide critical information regarding the effect of insulin glargine and omega 3 fatty acids on important clinical outcomes."

The ORIGIN (Outcome Reduction with an Initial Glargine Intervention) trial is sponsored by Sanofi-Aventis which manufactures insulin glargine. The study involves patients from every continent and is co-ordinated by researchers at the Population Health Research Institute at McMaster University and Hamilton Health Sciences in Hamilton, Ontario, Canada. The results are expected in 2011.

Recently, the following statement about the concerns was issued to the collaborating researchers involved in the study:

Regarding Glargine Insulin and Cancer

A recently published database analysis in the journal Diabetologia suggested a link between the use of glargine insulin and cancer. Although the results of this report were not confirmed in other database analyses, it has generated questions about the safety of glargine insulin. Such questions can best be answered by prospective, long-term follow-up of large numbers of patients enrolled in randomized trials of glargine versus other therapies.

The ORIGIN trial (Outcome Reduction with an Initial Glargine INtervention) randomized more than 12,500 people with dysglycemia (elevated glucose levels due to impaired fasting glucose, impaired glucose tolerance or early diabetes) to one injection of insulin glargine per day versus usual care. It is determining whether targeting normal fasting glucose levels with insulin glargine reduces cardiovascular outcomes compared to standard management. Participants have been followed for an average of four years to date for a total exposure of more than 50,000 person-years. Data are collected related to all major serious health outcomes, including cancers. Accumulating data are reviewed regularly by an Independent Data Monitoring Committee charged with auditing the safety of the trial. In light of the questions raised by the recent publication, this committee of experts has recently reviewed data related to cancers in both treatment groups and has concluded that there is no cause for concern and no reason to alter the design of the study for safety reasons.

The study is due to end in 2011, when detailed analyses will be published. In the meantime, the data will continue to be collected and audited for safety by this independent group. To maintain a high-quality and unbiased study, researchers and the manufacturer of insulin glargine do not (and will continue to not) have access to data summarizing outcomes by treatment group until the study is over.


Story Source:

The above story is based on materials provided by McMaster University. Note: Materials may be edited for content and length.


Cite This Page:

McMaster University. "Research Team Responds To Concerns About International Insulin Drug Trial." ScienceDaily. ScienceDaily, 17 August 2009. <www.sciencedaily.com/releases/2009/08/090811091838.htm>.
McMaster University. (2009, August 17). Research Team Responds To Concerns About International Insulin Drug Trial. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/08/090811091838.htm
McMaster University. "Research Team Responds To Concerns About International Insulin Drug Trial." ScienceDaily. www.sciencedaily.com/releases/2009/08/090811091838.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins